CR11803A - Pirrolopiridinas como inhibidores de cinasa - Google Patents

Pirrolopiridinas como inhibidores de cinasa

Info

Publication number
CR11803A
CR11803A CR11803A CR11803A CR11803A CR 11803 A CR11803 A CR 11803A CR 11803 A CR11803 A CR 11803A CR 11803 A CR11803 A CR 11803A CR 11803 A CR11803 A CR 11803A
Authority
CR
Costa Rica
Prior art keywords
pirrolopiridins
cinase
inhibitors
cinase inhibitors
compounds
Prior art date
Application number
CR11803A
Other languages
English (en)
Inventor
Le Huerou Yvan
F Blake James
W Gunwardana Indrani
J Mohr Peter
M Wallace Eli
Wang Bin
Chicarelli Mark
Michael Lyon
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11803(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR11803A publication Critical patent/CR11803A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de la Fórmula I son útiles para la inhibición de CHK1 y/o CHK2. También se revelan métodos para usar compuestos de la Fórmula I y esteroisómeros y sales farmacéuticamente aceptables de ellos.
CR11803A 2008-05-13 2010-11-19 Pirrolopiridinas como inhibidores de cinasa CR11803A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13

Publications (1)

Publication Number Publication Date
CR11803A true CR11803A (es) 2011-02-11

Family

ID=40810786

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11803A CR11803A (es) 2008-05-13 2010-11-19 Pirrolopiridinas como inhibidores de cinasa

Country Status (30)

Country Link
US (6) US8178131B2 (es)
EP (2) EP2990407B1 (es)
JP (2) JP5703212B2 (es)
KR (2) KR101657856B1 (es)
CN (3) CN102089307B (es)
AR (1) AR071717A1 (es)
AU (1) AU2009246402B2 (es)
BR (1) BRPI0913580B8 (es)
CA (1) CA2724262C (es)
CL (1) CL2009001152A1 (es)
CO (1) CO6321244A2 (es)
CR (1) CR11803A (es)
CY (1) CY1116692T1 (es)
DK (1) DK2307409T3 (es)
ES (1) ES2552643T3 (es)
HK (2) HK1152035A1 (es)
HR (1) HRP20151018T1 (es)
HU (1) HUE026160T2 (es)
IL (1) IL209258A (es)
MX (1) MX2010012449A (es)
NZ (1) NZ589318A (es)
PH (1) PH12013501779A1 (es)
PL (1) PL2307409T3 (es)
PT (1) PT2307409E (es)
RS (1) RS54358B1 (es)
RU (1) RU2517194C2 (es)
SI (1) SI2307409T1 (es)
TW (2) TWI554512B (es)
UA (1) UA111933C2 (es)
WO (1) WO2009140320A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2394759T3 (es) 2008-01-08 2013-02-05 Array Biopharma, Inc. Pirrolopiridinas como inhibidores de quinasa
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
AU2010233122B2 (en) * 2009-04-11 2015-09-17 Array Biopharma Inc. Checkpoint kinase 1 inhibitors for potentiating DNA damaging agents
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
JP5749341B2 (ja) 2010-08-20 2015-07-15 ハチソン メディファーマ リミテッド ピロロピリミジン化合物およびその使用
RU2017127088A (ru) * 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
ES2563152T3 (es) 2011-02-25 2016-03-11 Array Biopharma Inc. Compuestos de triazolopiridina como inhibidores de quinasa PIM
CA2834166A1 (en) 2011-04-29 2012-11-01 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
BR112014026367A2 (pt) 2012-04-23 2017-06-27 Genentech Inc 5-bromo-4-cloro-3-nitro-1h-pirrol[2,3-b]piridina e seu processo
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
MX369174B (es) * 2013-08-22 2019-10-30 Genentech Inc Proceso para la preparación de un compuesto.
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
WO2015048318A1 (en) * 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated A selective inhibitor of phosphatidylinositol 3-kinase-gamma
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016004305A2 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MA41599A (fr) 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
CN107708414B (zh) 2015-06-30 2022-02-25 首尔伟傲世有限公司 适用紫外线发光二极管的捕虫器
NZ741293A (en) 2015-11-04 2023-06-30 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
CN108779116A (zh) * 2015-12-22 2018-11-09 生命医药公司 多发性内分泌瘤蛋白-mll相互作用的抑制剂
CA3024180A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
MA53095A (fr) 2018-07-03 2021-05-12 Ifm Due Inc Composés et compositions pour traiter des états pathologiques associés à une activité de sting
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
JP2023540673A (ja) 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
IL308476A (en) 2021-05-14 2024-01-01 Syndax Pharmaceuticals Inc Inhibitors of the menin-mil interaction

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503783A (ja) 1993-10-14 1997-04-15 アボツト・ラボラトリーズ キノリジノン型化合物
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP1254115A2 (en) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6797825B2 (en) * 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1537106A1 (en) 2002-08-07 2005-06-08 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AR042667A1 (es) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
US20070149560A1 (en) 2003-03-14 2007-06-28 Astrazeneca Ab Novel fused triazolones and the uses thereof
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
AU2005236002A1 (en) * 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
TWI380816B (zh) * 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
AU2006232620A1 (en) 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors
ZA200710379B (en) 2005-05-20 2009-05-27 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
WO2007026664A1 (ja) * 2005-08-30 2007-03-08 Asahi Kasei Pharma Corporation スルホンアミド化合物
CA2627623C (en) * 2005-10-06 2014-04-22 Schering Corporation Methods for inhibiting protein kinases
US7776865B2 (en) 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
BRPI0619817B8 (pt) 2005-12-13 2021-05-25 Incyte Corp composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição
EP1979353A2 (en) 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
JP5606734B2 (ja) * 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
KR101514853B1 (ko) 2007-03-01 2015-04-24 노파르티스 아게 Ｐｉｍ 키나제 억제제 및 이들의 사용 방법
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
JP2011503084A (ja) 2007-11-07 2011-01-27 シェーリング コーポレイション 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用
ES2394759T3 (es) * 2008-01-08 2013-02-05 Array Biopharma, Inc. Pirrolopiridinas como inhibidores de quinasa
CN101965347B (zh) * 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
RU2017127088A (ru) 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1

Also Published As

Publication number Publication date
CN102089307A (zh) 2011-06-08
RU2517194C2 (ru) 2014-05-27
IL209258A (en) 2017-01-31
CN102089307B (zh) 2015-07-01
TWI554512B (zh) 2016-10-21
US8545897B2 (en) 2013-10-01
US20140100369A1 (en) 2014-04-10
TWI458727B (zh) 2014-11-01
CN109942575A (zh) 2019-06-28
SI2307409T1 (sl) 2015-11-30
CA2724262A1 (en) 2009-11-19
CN104926810B (zh) 2019-02-19
JP5703212B2 (ja) 2015-04-15
DK2307409T3 (en) 2015-09-21
EP2307409A1 (en) 2011-04-13
PH12013501779B1 (en) 2014-08-27
US20150322061A1 (en) 2015-11-12
KR20110008102A (ko) 2011-01-25
US20140243520A1 (en) 2014-08-28
US8981085B2 (en) 2015-03-17
EP2990407A1 (en) 2016-03-02
EP2990407B1 (en) 2019-10-16
CN104926810A (zh) 2015-09-23
ES2552643T3 (es) 2015-12-01
RU2010150786A (ru) 2012-06-20
RS54358B1 (en) 2016-04-28
KR20140093266A (ko) 2014-07-25
AU2009246402B2 (en) 2013-05-23
BRPI0913580B1 (pt) 2020-03-10
US20130045286A1 (en) 2013-02-21
HK1219950A1 (zh) 2017-04-21
KR101657856B1 (ko) 2016-09-19
US9365568B2 (en) 2016-06-14
BRPI0913580A2 (pt) 2015-10-20
BRPI0913580B8 (pt) 2021-05-25
JP2015098482A (ja) 2015-05-28
TW201529573A (zh) 2015-08-01
HRP20151018T1 (hr) 2015-10-23
PH12013501779A1 (en) 2014-08-27
IL209258A0 (en) 2011-01-31
NZ589318A (en) 2011-06-30
HK1152035A1 (en) 2012-02-17
EP2307409B1 (en) 2015-08-12
UA111933C2 (uk) 2016-07-11
KR101643426B1 (ko) 2016-07-27
CO6321244A2 (es) 2011-09-20
JP2011520896A (ja) 2011-07-21
HUE026160T2 (en) 2016-05-30
AU2009246402A1 (en) 2009-11-19
CL2009001152A1 (es) 2009-10-16
US9969727B2 (en) 2018-05-15
AR071717A1 (es) 2010-07-07
MX2010012449A (es) 2011-05-25
PT2307409E (pt) 2015-11-04
CY1116692T1 (el) 2017-03-15
US20160368916A1 (en) 2016-12-22
CA2724262C (en) 2017-08-15
US8178131B2 (en) 2012-05-15
WO2009140320A1 (en) 2009-11-19
US8758830B2 (en) 2014-06-24
PL2307409T3 (pl) 2016-01-29
US20110070317A1 (en) 2011-03-24
TW201002707A (en) 2010-01-16

Similar Documents

Publication Publication Date Title
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CR20150045A (es) Inhibidores de hepatitis c
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
EA201170872A1 (ru) Ингибиторы протеинкиназы
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
CR20140216A (es) 5,7-imidazo[1,2-c]pirimidinas sustituidas
CR11229A (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CO6361924A2 (es) Nuevas lactamas como inhibidores de beta secretasa
ECSP11010830A (es) Derivados de heteroarilo como inhibidores de dgat1
UY32977A (es) Novedosos compuestos como inhibidores de la caseina quinasa
PA8821301A1 (es) Inhibidores a base de hidroxamato de desacetilasas b
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
GT201000298A (es) 2,6-diamino-pirimidin-z-il-carboxamidas como inhibidores de syk o jak quinasas
NI201100035A (es) Agentes antifúngicos.
UY31775A (es) Compuestos heterocíclicos como inhibidores de mek
ATE481395T1 (de) Cyclohexylderivate
EA201400001A1 (ru) Новые производные фталазинонпирролопиримидинкарбоксамида
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
CU20100127A7 (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CU23955B1 (es) PIRIMIDINAS BICÍCLICAS FUSIONADAS COMO INHIBIDORES EFECTIVOS DE LA VÍA Pi3K/Akt
HN2010000739A (es) Inhibidores de quinasa c-fms